66 results
This study has been transitioned to CTIS with ID 2024-512676-36-00 check the CTIS register for the current data. * To decrease mortality in MS-LCH by an early switch of patients with risk organ involvement, who do not respond to front-line therapy,…
The primary objective is to perform a clinical validation of the analytical method for dried blood spot microsampling of cabozantinib, pazopanib, sunitinib, Lenvatinib, nivolumab, ipilimumab, pembrolizumab, atezolizumab or bevacizumab. The secondary…
To evaluate the efficacy of a new tumor-agnostic ctDNA assay, the ctDNA estimator, to detect newly developing tumors in Lynch carriers.
The objective of this study is to evaluate the efficacy of oral cabozantinib at adaily dose of 60 mg compared with 140 mg in subjects with progressive,metastatic MTC.
The aim of present study is to investigate if adapting the dosing factor based on TBW and therefore the CM volume to the tube voltage used, results in a more homogeneous liver enhancement. We hope to find a more homogeneous enhancement between…
Therefore the objective of this study is to test the feasibility of the detection of circulating tumor DNA of a variety of tumors in peripheral blood using a novel detection process.